Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Palmitic acid
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

2241674-94-0

2241674-94-0 structure

2241674-94-0 structure

Name: iNOs-IN-3
Chemical Name: iNOs-IN-3
CAS Number: 2241674-94-0
Molecular Formula: C₂₇H₂₄N₂O₅S
Molecular Weight: 488.55
Catalog: Research Areas Inflammation/Immunology
Create Date: 2022-09-07 21:05:27
Modify Date: 2025-09-18 13:27:19
iNOs-IN-3 (Compound 2d) is an orally active nitric oxide synthase (iNOS) inhibitor (IC50=3.342 µM). iNOs-IN-3 shows anti-inflammatory activity and can be used in LPS-induced acute lung injury (ALI) research[1].

Name	iNOs-IN-3

Description	iNOs-IN-3 (Compound 2d) is an orally active nitric oxide synthase (iNOS) inhibitor (IC50=3.342 µM). iNOs-IN-3 shows anti-inflammatory activity and can be used in LPS-induced acute lung injury (ALI) research[1].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
Target	IC50: 3.342 µM (iNOS)[1]
In Vitro	iNOs-IN-3 (25 μM; 24 h) inhibits LPS-induced RAW 264.7 cells[1]. iNOs-IN-3 (12.5 μM; 24 h) can decrease the expression of iNOS[1]. Cell Viability Assay[1] Cell Line: RAW 264.7 microphages Concentration: 25 μM Incubation Time: 24 hours Result: Showed higher inhibitory activity (IC50=14.72 µM) in LPS-induced RAW 264.7 cells. Cell Viability Assay[1] Cell Line: RAW 264.7 microphages Concentration: 12.5 μM Incubation Time: 24 hours Result: Inhibited the LPS-induced mRNA expression of iNOS obviously. Cell Viability Assay[1] Cell Line: RAW 264.7 microphages Concentration: 12.5 μM Incubation Time: 24 hours Result: Inhibited the expression of TNF-α, IL-6, and IL-1β at 12.5 µM.
In Vivo	iNOs-IN-3 (oral administration; 12.5 mg/kg; once) treatment shows anti-inflammatory activity against xylene-induced ear edema in mice[1]. iNOs-IN-3 (oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once) protects against LPS-induced acute lung injury[1]. Animal Model: Xylene-induced mice[1] Dosage: 12.5 mg/kg Administration: Oral administration; 12.5 mg/kg; once Result: Showed better activity than the positive control. Animal Model: LPS-induced acute lung injury (ALI) mice[1] Dosage: 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg Administration: Oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once Result: Attenuated the pathological lesions dose-dependently, such as decreased inflammatory infiltration and pulmonary congestion. Inhibited LPS-induced lung edema dose-dependently.
References	[1]. Li Tang, et al. Design and synthesis of new disubstituted benzoxazolone derivatives that act as iNOS inhibitors with potent anti-inflammatory activity against LPS-induced acute lung injury (ALI). Bioorg Med Chem. 2020 Nov 1;28(21):115733.

Molecular Formula	C₂₇H₂₄N₂O₅S
Molecular Weight	488.55

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.